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Abstract
Background: Congenital hyperinsulinism (CHI) is the most common cause of persistent hypoglycaemia in infancy
that leads to unfavourable neurological outcome if not treated adequately. In patients with severe diffuse CHI it
remains under discussion whether pancreatic surgery should be performed or intensive medical treatment with the
acceptance of recurrent episodes of mild hypoglycaemia is justified. Near-total pancreatectomy is associated with
high rates of insulin-dependent diabetes mellitus and exocrine pancreatic insufficiency. Little is known about the
management and long-term glycaemic control of CHI patients with diabetes after pancreatic surgery. We searched
the German/Austrian DPV database and compared the course of 42 CHI patients with diabetes to that of patients
with type 1 diabetes mellitus (T1DM). Study groups were compared at diabetes onset and after a follow-up period
of 6.1 [3.3–9.7] (median [interquartile range]) years.
Results: The majority of CHI patients with diabetes were treated with insulin (85.2% [70.9–99.5] at diabetes onset,
and 90.5% [81.2–99.7] at follow-up). However, compared to patients with T1DM, significantly more patients in the
CHI group with diabetes were treated with conventional insulin therapy (47.8% vs. 24.4%, p = 0.03 at diabetes onset,
and 21.1% vs. 6.4% at follow-up, p = 0.003), and only a small number of CHI patients were treated with insulin pumps.
Daily insulin dose was significantly lower in CHI patients with diabetes than in patients with T1DM, both at diabetes
onset (0.3 [0.2–0.5] vs. 0.6 IE/kg/d [0.4–0.8], p = 0.003) and follow-up (0.8 [0.4–1.0] vs. 0.9 [0.7–1.0] IE/kg/d, p = 0.02), while
daily carbohydrate intake was comparable in both groups. Within the first treatment year, HbA1c levels were significantly
lower in CHI patients with diabetes (6.2% [5.5–7.9] vs. 7.2% [6.5–8.2], p = 0.003), but increased to a level comparable to
that of T1DM patients at follow-up. Interestingly, in CHI patients, the risk of severe hypoglycaemia tends to be higher
only at diabetes onset (14.8% vs. 5.8%, p = 0.1).
Conclusions: In surgically treated CHI patients insulin treatment needs to be intensified in order to achieve good
glycaemic control. Our data furthermore emphasize the need for improved medical treatment options for patients with
diazoxide- and/or octreotide-unresponsive CHI.
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Background
Congenital hyperinsulinism (CHI) is a heterogeneous
metabolic disorder that is characterized by the unregu-
lated release of insulin from pancreatic beta cells leading
to recurrent episodes of hypoglycaemia [1]. CHI is a rare
disease, affecting approximately 1 in 50.000 newborns in
Europe and the United States, but the most common
cause of persistent hypoglycaemia in infancy [2]. Rapid
diagnosis and adequate therapy that aims at maintaining
blood glucose concentrations within a physiological
range are crucial to prevent hypoglycaemic brain dam-
age and to achieve good neurodevelopmental outcomes
[3–8]. Management of CHI involves nutritional, medical
and surgical intervention, depending on the underlying
histologic and genetic subtype of CHI [1]. Management
of diffuse CHI (DCHI) that accounts for most CHI cases
still remains a major challenge. Most patients require a
combination of different medications, including off-label
use of drugs like somatostatin analogues or sirolimus,
and additional nutritional therapy to achieve sufficient gly-
caemic control [9–14]. Importantly, in many medically
treated CHI patients disease severity reduces over time
[15, 16]. Still, there is a persisting risk of hypoglycaemia
and subsequent neurodevelopmental impairment in med-
ically and nutritionally treated DCHI. In those patients
with severe medically-unresponsive DCHI near-total pan-
createctomy, i.e. resection of approximately 95–98% of
pancreatic tissue may be required [17, 18]. The outcome
of patients with DCHI treated with near-total pancreatec-
tomy is variable and often unsatisfactory. High rates of
persisting hypoglycaemia (up to 60%), hyperglycaemia (al-
most 100% at 11 years post-surgery) and exocrine pancre-
atic insufficiency (almost 50%) have been reported in
patients with DCHI following pancreatectomy [19–23].
Even though all CHI patients treated by near-total pan-
createctomy eventually develop insulin-dependent diabetes
mellitus, very little is known about the characteristics of
this specific diabetes type, particularly the intensity of dia-
betes management, the associated risk of hypoglycaemia
and long-term glycaemic control.
We chose a multi-centre approach and searched the
German/Austrian Diabetes Patienten Verlaufsdokumen-
tation (DPV) database to compare the course of 42 CHI
patients with diabetes to that of age-matched patients
with type 1 diabetes mellitus (T1DM). Data were com-
pared at diabetes onset and after a median follow-up
period of 6.1 [3.3–9.7] years (median [interquartile
range]). Here we provide objective information on treat-
ment modality (conventional insulin therapy, intensified
insulin therapy, insulin pump), insulin dose and daily
carbohydrate intake, glycaemic control and the risk of
hypoglycaemia in CHI patients following pancreatic sur-
gery. Our data emphasize the need to reconsider the
management and treatment goals in this particular
group of diabetes patients, and strengthen the need for
alternative treatment options for patients with DCHI.
Methods
DPV registry
Data were extracted from the DPV registry, a nationwide
prospective multicentre initiative that records demo-
graphic and clinical data of children and adults with any
type of diabetes. More than 400 centres in Germany,
Austria, Switzerland and Luxembourg participate in the
DPV initiative. Each centre transmits its data biannually
in an anonymous form to the University of Ulm,
Germany for central data acquisition and analysis. Data
are screened for inconsistency and, if applicable, re-
ported back to centres for re-confirmation or correction.
Until September 2016 471.247 patients with diabetes
were registered in the electronic computer based docu-
mentation software DPV. The DPV initiative and the
analysis of anonymized data related to quality of care
were approved by the ethics committee of the University
of Ulm.
For the present analysis we included all subjects with
T1DM or congenital hyperinsulinism and pancreatic
surgery aged younger than 26 years. For each patient,
data from the first treatment year (duration of diabetes
less than 1 year) and from the most recent treatment
year were extracted and analysed.
The final study sample encompassed 54.747 and
65.982 patients with T1DM, and 27 and 42 patients with
CHI and diabetes at diabetes onset and follow-up,
respectively.
Data analysis
Diabetes management was categorized as insulin therapy
or therapy with oral antidiabetic drugs (OADs). Insulin
therapy was further subclassified as (1) conventional in-
sulin therapy (CT), if 1–3 times of injections per day
were documented, or (2) intensified insulin therapy
(ICT), if 4–8 times of injections per day were docu-
mented, or (3) continuous subcutaneous insulin infusion
(CSII). Insulin requirements are expressed as total daily
insulin dose (IE/d) and daily insulin dose per kilogram
(kg) body weight (IE/kg/d). Carbohydrate intake was cal-
culated in carbohydrate units (CU, one unit equals about
12 g carbohydrates), and expressed as total daily carbo-
hydrate intake (CU/d) and daily carbohydrate intake per
kg body weight (CU/kg/d). Glycaemic control was deter-
mined by glycated haemoglobin A1c (HbA1c) level.
HbA1c level from different centres were mathematically
standardized to the reference range of the Diabetes Con-
trol and Complication Trial (DCCT) (4.05–6.05%). Se-
vere hypoglycaemia was defined according to the ISPAD
guidelines, i.e. an episode of hypoglycaemia associated
with severe cognitive impairment requiring external
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assistance by another person [24]. Body mass index
(BMI) was calculated as weight in kg divided by square of
the height in meters (kg/m2). C-Peptide secretion in μg/L
was categorized as either < 1 μg/L (negative) or > 1 μg/L
(positive).
Statistics
Descriptive statistics are given as median [Q1-Q3] or as
percentages. Differences between individuals with T1DM
and subjects with CHI and diabetes were analysed using
Kruskal-Wallis test for continuous variables and χ2-test
for dichotomous variables. False discovery rate was used
to correct for multiple comparisons. Comparisons be-
tween the first year after manifestation and the most re-
cent treatment year were calculated by using t-test for
continuous variables, and McNemar test for dichotom-
ous variables. A two-sided p-value < 0.05 was considered
significant. SAS version 9.4 software (SAS Institute,
Cary, NC, USA) was used for statistical analysis.
Results
Patient characteristics
Fourty-five patients with CHI and diabetes following
pancreatic surgery are currently registered in the
German/Austrian DPV database. Data on diabetes man-
agement, insulin requirements, carbohydrate intake, gly-
caemic control (HbA1c level), and C-peptide secretion
were available for up to 27 of these patients from the
first year after manifestation (hereafter specified as “dia-
betes onset” data), and for up to 42 of these patients
from the most recent treatment year (hereafter specified
as “follow-up” data). Patients with T1DM served as con-
trol and were directly compared to the CHI patients
with diabetes (Table 1). Data at diabetes onset were ob-
tained after a median duration of diabetes of 0.4 (0.2–0.5;
p = 0.3) years in the CHI group versus (vs.) 0.3 (0.2–0.5)
years in the T1DM group. At follow-up, median duration
of diabetes was 6.7 (4.6–13.6; p = 0.12) years in the CHI
group vs. 6.1 (3.3–9.7) years in the T1DM group (Fig. 1a).
In CHI patients median period between pancreatic sur-
gery and diabetes manifestation was 10.3 [4.9–12.5] years
(Fig. 1b).
There was no significant difference in BMI (19.2
[17.5–21.6] kg/m2 in T1DM patients vs. 20.0 [17.8–23.3]
kg/m2 in CHI patients, and 22.1 [19.7–24.7] kg/m2 in
T1DM patients vs. 22.6 [20.3–25.3] kg/m2 in CHI patients
at diabetes onset and follow-up, respectively; p = 0.6 and
p = 0.9) and age at diabetes onset (9.8 [7.0–13.0] years in
the CHI group, and 9.7 [6.0–13.0] in the T1DM group,
p = 0.7) (Fig. 1c,d).
A large number of patients with CHI and diabetes are
treated with conventional insulin therapy, and only a
small number with insulin pumps
The vast majority of CHI patients with diabetes were
treated with insulin (85.2% at diabetes onset, and 90.5%
at follow-up). At follow-up a small proportion of CHI
patients with diabetes were treated with OADs (4.8%), of
which 2,4% were treated with metformin (Fig. 2a). We
further compared insulin regimen between CHI patients
with diabetes and T1DM patients at diabetes onset
and at follow-up, i.e. the proportion of patients
treated with CT, ICT and CSII (Fig. 2b). Both, within
the first treatment year, but also at follow-up, signifi-
cantly more patients in the CHI group with diabetes
were treated with CT (47,8% vs. 24.4% patients with
T1DM, p = 0.03; and 21.1% vs. 6.4% patients with
T1DM at follow-up, p = 0.003), and only a small num-
ber of CHI patients were treated with CSII (8.7% vs.
15.2% patients with T1DM, p = 0.48; and 15.8% [3.6–27.9]
vs. 36.7% patients with T1DM at follow-up, p = 0.03).
Within the first treatment year, the majority of T1DM pa-
tients were treated with ICT (60.3%) whereas the majority
of CHI patients with diabetes were treated with CT
(47.8%). However, at follow-up, standard treatment for
both, CHI patients and T1DM patients was ICT (63.2%
vs. 56.9% patients with T1DM, p = 0.56). We also analysed
the number of injection times per day in CHI pa-
tients with diabetes and T1DM patients (Fig. 2c):
there was no significant difference at diabetes onset,
whereas at follow-up, T1DM patients had significantly
more injection time points per day than CHI patients
with diabetes (4.3 vs. 3.5 within the first treatment
year, p = 0.19 and 4.7 vs. 4.2 at follow-up, p = 0.03).
Within the first treatment year there was furthermore
a tendency towards a lower proportion of insulin ana-
logues used as basal insulin supplementation in CHI
patients with diabetes (20% vs. 26% in patients with
T1DM, p = 0.8). However, at follow-up the use of in-
sulin analogues had increased 3-fold and was similar
in both groups (62.1% vs. 60.2% in patients with
T1DM, p = 0.77).
Within the first year of antidiabetic treatment, the risk of
severe hypoglycaemia is high in CHI patients with
diabetes
The risk of severe hypoglycaemia tends to be higher
in CHI patients with diabetes than in patients with
Table 1 Study sample
1st treatment year
(diabetes onset)
recent-treatment year
(follow-up)
n patients (T1DM and CHI) 54,774 66,024
n patients with CHI 27 42
age (years) 10 [6.3–13.3] 16.3 [12.9–17.9]
male (%) 53.8 52.4
BMI (kg/m2) 19.2 [17.5–21.6] 22.1 [19.7–24.7]
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T1DM, particularly within the first year of treatment
(14.8% vs. 5.8% patients with T1DM, p = 0.11) (Fig. 3).
However, whereas severe hypoglycaemia was relatively
frequent within the first year of treatment in CHI pa-
tients, the risk decreased to a proportion comparable
to that of T1DM patients at follow-up (9.5% vs. 8.3%
patients with T1DM, p = 0.8).
Within the first treatment year, glycaemic control is
relatively good in CHI patients with diabetes, but
significantly deteriorates as diabetes progresses
While patients with T1DM typically had an increased
HbA1c level at diabetes onset (7.2% [6.5–8.2]), this was
not always the case in patients with CHI (6.2% [5.5–7.9],
p = 0.003.
However, as diabetes progressed, glycaemic control
significantly worsened in both groups, and at follow-up
CHI patients had reached a similar level of control as
patients with T1DM (HbA1c 7.5% [6.5–9.1] vs. 7.9%
[7.1–9.1], p = 0.12) (Fig. 4).
In CHI patients with diabetes, C-peptide secretion
progressively declines as diabetes progresses
For the evaluation of C-peptide secretion as a marker of
residual beta cell function, patients were assigned to one
of two categories: (I) C-peptide secretion < 1 μg/L (nega-
tive), (II) C-peptide secretion > 1 μg/L (positive) (Fig. 5).
Within the first treatment year, the majority of T1DM
patients fell into the first category (77.9%), whereas the
majority of CHI patients with diabetes fell into category
(II) (63.6%) (Fig. 5a). As diabetes progressed, C-peptide
secretion declined in both, T1DM patients and CHI pa-
tients with diabetes. However, compared to patients with
T1DM, at follow-up significantly more patients in the
CHI group could still be assigned to the second category
(50% vs. 16.8%, p = 0.04) (Fig. 5b).
Daily insulin dose is relatively low in CHI patients with
diabetes. Daily carbohydrate intake is comparable to that
of type 1 diabetic patients
Compared to patients with T1DM, total daily insulin dose
and insulin dose per kg body weight were significantly
d
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Fig. 1 Selected characteristics of CHI patients with diabetes compared to patients with T1DM. a Median duration of diabetes (years); n = 27 (diabetes
onset) and 42 (follow-up) CHI patients with diabetes, and n = 54,747 (diabetes onset) and 65,982 (follow-up) patients with T1DM; b Median period
between pancreatic surgery and diabetes onset in CHI patients with diabetes; n = 22; c BMI (kg/m2); n = 19 (diabetes onset) and 37 (follow-up) CHI
patients with diabetes, and n = 33,326 (diabetes onset) and 58,388 (follow-up) patients with T1DM d Age at diabetes onset; n = 27 CHI patients with
diabetes, and n = 54,774 patients with T1DM. Significance determined by p < 0.05 using Wilcoxon test
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analogues as basal insulin supplementation; n= 20 (diabetes onset) and 29 (follow-up) CHI patients with diabetes, and n= 43,378 (diabetes onset) and
39,546 (follow-up) patients with T1DM. All values are means. *P< 0.05. Significance determined by p < 0.05 using χ2-test
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lower in CHI patients with diabetes, both within the first
treatment year and at follow-up (Fig. 6a and b): daily insu-
lin dose was 11.8 IE [10.1–18.5] vs. 18.8 IE [11–31.5] in
patients with T1DM, p = 0.03 at diabetes onset, and 41 IE
[18.2–58] vs. 52.3 IE [35.3–68.7] in patients with T1DM,
p = 0.02 at follow-up; insulin dose per kg body weight was
0.3 IE [0.2–0.5] vs. 0.6 IE [0.43–0.78] in patients with
T1DM, p = 0.003 at diabetes onset, and 0.8 IE [0.4–1.0] vs.
0.9 IE [0.7–1.1] in patients with T1DM, p = 0.02 at
follow-up.
Daily basal insulin dose tended to be lower in CHI pa-
tients with diabetes within the first treatment year (6.3 IE
[4–10] vs. 8.4 IE [5–14] in patients with T1DM, p = 0.12),
a trend that reached significance as diabetes progressed
(16 IE [7.7–24] vs. 23.2 IE [15.2–31.1] in patients with
T1DM, p = 0.02 at follow-up) (Fig. 6c). Surprisingly, re-
lated to total daily insulin, basal insulin requirements were
relatively high in patients with CHI within the first treat-
ment year (53.2% of total daily insulin vs. 44.7% in patients
with T1DM), but markedly declined over time (39% vs.
44.4% in patients with T1DM at follow-up).
Daily prandial insulin dose were lower in CHI patients
with diabetes both, at diabetes onset (8.5 IE [2–12] vs.
10.8 IE [5.9–18.5] in patients with T1DM, p = 0.07) and
at follow-up (22 IE [10–33.5] vs. 28 IE [18–38.8] in pa-
tients with T1DM, p = 0.05) (Fig. 6d).
Interestingly, there was no significant difference in
total daily carbohydrate intake and daily carbohydrate
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intake per kg body weight between CHI patients with
diabetes and those with T1DM. In fact, in CHI patients, re-
ported daily carbohydrate intake tended to be slightly
lower compared to patients with T1DM (Fig. 6e and f): re-
ported total daily carbohydrate intake was 15CU [11–16.5]
vs. 16CU [13–19] in patients with T1DM, p = 0.19 at dia-
betes onset, and 16.8CU [13–20] vs. 17CU [14–20] in pa-
tients with T1DM, p = 0.57 at follow-up; carbohydrate
intake per kg body weight was 0.4CU [0.3–0.4] vs. 0.4CU
[0.3–0.5] in patients with T1DM, p = 0.13 at diabetes onset,
and 0.3CU [0.2–0.4] vs. 0.3CU [0.2–0.4] in patients with
T1DM, p = 0.57 at follow-up.
Discussion
Patients with severe diffuse CHI typically require pro-
longed nutritional and medical treatment to avoid
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(diabetes onset) and 38 (follow-up) CHI patients with diabetes, and n= 51,704 (diabetes onset) and 62,829 (follow-up) patients with T1DM. b Daily insulin
dose per kg body weight (IE/kg/d); n= 18 (diabetes onset) and 35 (follow-up) CHI patients with diabetes, and n= 32,304 (diabetes onset) and 57,206
(follow-up) patients with T1DM. c Total daily basal insulin dose (IE/d); n= 22 (diabetes onset) and 35 (follow-up) CHI patients with diabetes, and n= 51,145
(diabetes onset) and 62,440 (follow-up) patients with T1DM. d Total daily prandial insulin dose (IE/d); n= 21 (diabetes onset) and 37 (follow-up) CHI
patients with diabetes, and n= 50,454 (diabetes onset) and 62,246 (follow-up) patients with T1DM. e Total daily carbohydrate intake (CU/d); n= 18
(diabetes onset) and 34 (follow-up) CHI patients with diabetes, and n= 45,494 (diabetes onset) and 58,655 (follow-up) patients with T1DM. f Daily
carbohydrate intake per kg body weight (CU/kg/d); n= 16 (diabetes onset) and 31 (follow-up) CHI patients with diabetes, and n= 28,202 (diabetes onset)
and n= 53,380 (follow-up) patients with T1DM. All values are median ± lower and upper quartile. *P< 0.05. Significance determined by p< 0.05 using
Wilcoxon test
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episodes of severe symptomatic hypoglycaemia and to
maintain blood glucose concentrations within a range
regarded as safe with respect to brain damage [9].
The development of new drug formulations, e.g. syn-
thetic somatostatin analogues with prolonged half-life,
facilitated medical treatment of DCHI to some extent
[9–12, 25–27]. More recently, the efficacy of the mam-
malian target of rapamycin (mTOR) inhibitor sirolimus
has been investigated in critically ill CHI patients unre-
sponsive to diazoxide and octreotide [13]. Successful
outcomes have been achieved in some patients treated with
sirolimus, including a neonate with severe HH in
Beckwith-Wiedemann Syndrome [28–32]. However, others
have published on limited therapeutic success at the ex-
pense of serious side effects, and therefore extreme cau-
tious use of sirolimus has been advised in children with
CHI [14, 33, 34]. In the past, many medically-unresponsive
DCHI patients underwent extensive pancreatectomy in an
ultimate attempt to prevent severe hypoglycaemia [18, 35].
Still, near-total pancreatectomy (typically a 95% resection)
remains the last resort to prevent hypoglycaemic brain
damage in medically unresponsive severe DCHI [1, 35].
However, it has widely been proven in previous studies that
surgical intervention is never curative in children with
DCHI [7, 19–21, 23, 36, 37]. In fact, the long-term results
of surgical intervention in children with DCHI are very un-
satisfactory. Several groups revealed high incidence rates of
diabetes mellitus after extensive pancreatectomy (> 85%)
[19–23]. Long-term follow up data prove that in CHI pa-
tients the incidence of insulin-dependent diabetes mellitus
is almost 100% 10–15 years after near-total pancreatec-
tomy [19, 20]. Given that almost all DCHI patients treated
with near-total pancreatectomy eventually develop diabetes
mellitus, surprisingly little is known about their manage-
ment and long-term glycaemic control. Recommendations
how intense these patients can or should be treated do not
exist. Treatment regimen of these patients therefore mostly
depends on single-centre experiences.
Our data reveal that most CHI patients with diabetes
appear to be treated less intense than T1D patients, as
significantly more CHI patients with diabetes are treated
with conventional insulin therapy, both at diabetes onset
and at follow-up. This is also expressed by the overall
number of injection times per day, which tends to be
lower in CHI patients, particularly at follow-up, and by
the less common use of basal insulin analogues within
the first treatment year. Furthermore, only a very small
number of CHI patients with diabetes are treated with
insulin pumps (Fig. 2). This might be ascribed to the
large proportion of CHI patients with residual beta cell
function at diabetes onset (Fig. 5), and/or reflect the physi-
cian’s attempt to minimize the risk of hypoglycaemia. In
fact, severe hypoglycaemia is more frequent in CHI pa-
tients with diabetes than in patients with T1DM, probably
due to unregulated release of insulin from the remaining,
yet malfunctioning beta cells. Impaired counterregulatory
response to hypoglycaemia owing to glucagon deficiency,
and enhanced peripheral insulin sensitivity that has been
shown in adults with pancreatogenic diabetes (i.e. diabetes
secondary to diseases of the exocrine pancreas or pancrea-
tectomy) further increase the risk of hypoglycaemia after
pancreatic surgery [38–40]. Interestingly, our data reveal
that the risk of severe hypoglycaemia tends to be higher
only within the first treatment year, while it decreases to a
rate comparable to that of T1DM patients as diabetes pro-
gresses (Fig. 3). Therefore, in CHI patients with diabetes, a
more intensive approach in the course of diabetes seems
to be feasible, particularly with regard to the level of gly-
caemic control achieved in these patients at follow-up: at
diabetes onset, some CHI patients with diabetes still had
normal HbA1c level, while at follow-up HbA1c had in-
creased significantly. However, it has to be taken into
consideration that in CHI patients with early diabetes
postprandial hyperglycaemia typically alternate with recur-
rent episodes of hypoglycaemia and therefore HbA1c ini-
tially remains low. As a measure of residual beta cell
function, we furthermore evaluated random C-peptide se-
cretion. Both, at diabetes onset and at follow-up, endogen-
ous insulin release is higher in CHI patients with diabetes
than in patients with T1DM, apparently due to the
remaining beta cell mass (Fig. 5). Consistently, insulin re-
quirements are lower in CHI patients with diabetes com-
pared to patients with T1DM, particularly as diabetes
progresses (Fig. 6 a,b). Residual secretory capacity and en-
hanced peripheral insulin sensitivity probably account for
low insulin requirements of CHI patients with diabetes [40].
However, a persisting tendency towards hypoglycaemia and
fear of hypoglycaemia may also have an impact on basal and
prandial insulin dose.
Conclusion
This multicentre approach provides objective informa-
tion on the management of CHI patients with diabetes
following pancreatic surgery. Of note, the diabetes regis-
try includes only diabetes-related data. Limited data
were available about the treatment prior to diabetes, the
extent of pancreatectomy (i.e. partial vs. subtotal vs. near
total pancreatectomy) and about the underlying genetics
of CHI. As extensive pancreatic resection appears to be
a prerequisite for the development of diabetes, we pre-
sume that CHI patients in our cohort were treated by
subtotal or near-total pancreatectomy [7, 35].
Our data indicate, that CHI patients with diabetes
often require an intensive insulin therapy comparable to
that of type 1 diabetic patients, particularly when dia-
betes progresses and residual beta cell function further
declines. At this time, a more rigorous insulin regimen is
necessary to improve the long-term metabolic outcome
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of diabetic CHI patients, particularly with respect to dia-
betic long-term complications. This means that in those
infants with severe diffuse CHI intensive medical treatment
including off-label use of drugs, nutritional therapy and ac-
ceptance of recurrent episodes of mild hypoglycaemia has
to be weighed against the long-term risks and side effects
of surgical management. In view of this dilemma, i.e. poor
outcome and/or a high burden for patients and family
members with both approaches, there is an urgent need
for alternative medical treatment options for patients with
CHI.
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